United Therapeutics Corporation $UTHR Shares Acquired by Vanguard Personalized Indexing Management LLC

Key Points

• Vanguard Personalized Indexing Management LLC increased its stake in United Therapeutics Corporation by 16.7%, acquiring 1,170 additional shares and bringing its total holdings to over 8,184 shares valued at approximately $2.35 million.
• United Therapeutics reported earnings of $6.41 EPS for the last quarter, which was $0.39 below analyst expectations, while quarterly revenue rose 11.7% year-over-year to $798.60 million.
• Analysts have varying ratings for UTHR, with Bank of America raising its target price to $463.00 while Oppenheimer set a new target of $575.00, highlighting a consensus rating of "Moderate Buy".

Vanguard Personalized Indexing Management LLC boosted its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 16.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,184 shares of the biotechnology company's stock after purchasing an additional 1,170 shares during the quarter. Vanguard Personalized Indexing Management LLC's holdings in United Therapeutics were worth $2,352,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Farther Finance Advisors LLC grew its stake in shares of United Therapeutics by 20.3% during the 1st quarter. Farther Finance Advisors LLC now owns 456 shares of the biotechnology company's stock valued at $140,000 after buying an additional 77 shares during the period. Fifth Third Bancorp grew its position in United Therapeutics by 22.7% during the first quarter. Fifth Third Bancorp now owns 487 shares of the biotechnology company's stock valued at $150,000 after acquiring an additional 90 shares during the period. Sound Income Strategies LLC purchased a new stake in United Therapeutics during the first quarter valued at about $49,000. Exchange Traded Concepts LLC raised its holdings in shares of United Therapeutics by 14.3% in the 1st quarter. Exchange Traded Concepts LLC now owns 4,643 shares of the biotechnology company's stock worth $1,431,000 after purchasing an additional 581 shares during the period. Finally, Kingswood Wealth Advisors LLC lifted its stake in shares of United Therapeutics by 16.0% in the 1st quarter. Kingswood Wealth Advisors LLC now owns 741 shares of the biotechnology company's stock valued at $228,000 after purchasing an additional 102 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Down 0.3%

Shares of NASDAQ UTHR opened at $432.19 on Thursday. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $459.48. The business has a 50 day moving average price of $380.39 and a two-hundred day moving average price of $326.20. The firm has a market cap of $19.50 billion, a PE ratio of 16.87, a price-to-earnings-growth ratio of 4.73 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million for the quarter, compared to analysts' expectations of $802.13 million. During the same quarter last year, the company posted $5.85 earnings per share. The business's quarterly revenue was up 11.7% compared to the same quarter last year. On average, analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on UTHR shares. Bank of America increased their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 2nd. JPMorgan Chase & Co. decreased their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research note on Tuesday, July 8th. HC Wainwright raised their target price on shares of United Therapeutics from $400.00 to $500.00 and gave the company a "buy" rating in a research note on Friday, September 5th. Oppenheimer upped their price target on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an "outperform" rating in a research report on Friday, September 5th. Finally, Jefferies Financial Group raised their price objective on United Therapeutics from $432.00 to $564.00 and gave the company a "buy" rating in a research report on Tuesday, September 2nd. Ten investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $457.21.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of the business's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $308.75, for a total value of $3,396,250.00. Following the sale, the executive vice president owned 36,781 shares in the company, valued at $11,356,133.75. The trade was a 23.02% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 288,435 shares of company stock valued at $117,231,067. 10.30% of the stock is owned by company insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.